Sun Pharma Share Price: Stock Analysis, History, and Forecast

After the pandemic hit the countries, there has been a rise in demand for pharmaceutical products for fever, cough and even vaccinations. The heightened demand led to increased stock prices of the pharmaceutical companies. One such company, Sun Pharma, has seen a surge in demand for its pharmaceutical products with increased stock value that finally culminated into augmented share price. Moreover, its stock has also proven to bear one of the highest returns on investment in the stock market. Given its impressive profile, it is plausible that the Sun Pharma shares might prove to be a lucrative long-term investment option for potential investors.   

The stock has gained a competitive edge in the world pharmaceutical market by already being number one in India.

Make your investment wisely by understanding the current price of Sun Pharma, Sun Pharma share price forecast, historical performance and more in detail.

Sun Pharma Share Price Today

Tabulated below is the data and performance of Sun Pharma Share Price today:

Note: The above information of Sun Pharma share price today is mentioned as per the data available on 27th April, 2022.

Sun Pharma Share Price NSE

• Live Sun Pharma Share Price NSE: ₹910.55
• Previous Close: ₹918.05
• Opening Price: ₹910.05
• High: ₹1,009.85
• Low: ₹826.25
• Sun Pharma Share Price BSE
• Live Sun Pharma Share Price BSE: ₹912.15
• Previous Close: ₹918.25
• Opening Price: ₹908.20
• High: ₹921.50
• Low: ₹908.20

Sun Pharma Historical Share Price

The performance data of Sun Pharma stock price from 2016 to 2019 in mentioned in the table below:

Summary Of Historical SunPharma Stock Price

• Highest: ₹898.45
• Lowest: ₹344.55
• Difference: ₹553.90
• Average: ₹581.82
• Chg. %: -47.26

Sun Pharma Share Price Target Forecast

The below given Sun Pharma share price forecast may be subjected to change in the near future as per their stock performance. However, the below tabulated Sun Pharma share price forecast is as per the performance of stock in April 2022.

Sun Pharma Company Information

Sun Pharmaceutical Industries Ltd. is an Indian-based multinational pharma company started in 1983. The company is the largest pharmaceutical organisation in India and the fourth largest dealer of generic medicines in the world. Sun Pharmaceutical is headquartered in Mumbai (Maharashtra). The company works on the highest pharma integrity to offer the best and most affordable pharma solutions to the people. It deals in the following segments:

• Generics
• Branded Generics
• Over-the-counter (OTC) Medicines
• Speciality Pharmaceuticals
• Antiretrovirals (ARVs)
• Active Pharmaceutical Ingredients (APIs)
• Intermediates

Management of Sun Pharma

Sun Pharma has the top management in the country. Below listed are the management roles and responsibilities of Sun Pharmaceuticals.

Sun Pharma Company Location

Here is the location information and the contact details of Sun Pharma. 

Corporate Office 

• Address: Sun Pharmaceutical Industries Ltd., SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai 400063
• Telephone Number: (+91 22) 4324 4324
• Fax Number: (+91 22) 4324 4343

Media Contacts

• Address: Global Headquarters of Sun Pharmaceutical Industries Ltd., Mumbai, India
• Telephone Number: (+91 22) 4324 4324
• Email ID: gaurav.chugh@sunpharma[dot]com

Don’t miss it!

Sun Pharma Company Performance

Sun Pharma Stock Returns in 2020 and 2021

The SunPharma stock price was on a new high in 2020 and 2021. In the table below, the stock price fluctuation and performance of Sun Pharma is mentioned in detail.

Summary of SunPharma Stock Price in 2020 and 2021

• Highest: ₹ 851.00
• Lowest: ₹ 312.00
• Difference: ₹ 539.00
• Average: ₹ 593.78
• Chg. %: 95.51

Sun Pharma Listings and Indices

Given below are the key dates, listings and indices of Sun Pharma. 

Key Dates

• Incorporation Date: 01/03/1993
• Public Issue Date: 06/10/1994
• Year Ending Month: March
• AGM Month: August
• Book Closure Start Date: 25/08/2021
• Book Closure End Date: 31/08/2021
• Listing Information
• Face Value: 1.0
• Market Lot Of Equity Shares: 1
• BSE Code: 524715
• BSE Group: A

Sun Pharma Share Indices

• MCX-SX 40 Index
• NIFTY 100
• NIFTY 200
• NIFTY 50
• NIFTY 50 Equal Weight
• NIFTY 500
• NIFTY 500 Multicap 50:25:25 Index
• NIFTY Growth Sectors 15
• NIFTY Healthcare Index
• NIFTY India Manufacturing Index
• NIFTY LargeMidcap 250
• NIFTY Pharma
• NIFTY Total Market
• NIFTY100 Equal Weight
• NIFTY100 Liquid 15
• NIFTY50 USD
• NIFTY50 Value 20
• S&P BSE 100
• S&P BSE 100 ESG Index
• S&P BSE 100 LargeCap TMC Index
• S&P BSE 200
• S&P BSE 250 LargeMidCap Index
• S&P BSE 500
• S&P BSE AllCap
• S&P BSE Carbonex
• S&P BSE Dividend Stability Index
• S&P BSE Dollex – 100
• S&P BSE Dollex – 200
• S&P BSE Dollex – 30
• S&P BSE Greenex
• S&P BSE Healthcare
• S&P BSE India Manufacturing
• S&P BSE LargeCap
• S&P BSE LargeMidCap
• S&P BSE Sensex
• S&P BSE Sensex 50

Company Also Listed On The Following

• Bangalore Stock Exchange Ltd.
• Calcutta Stock Exchange Association Ltd.
• Cochin Stock Exchange Ltd.
• Delhi Stock Exchange Assoc. Ltd.
• Hyderabad Stock Exchange Ltd
• Jaipur Stock Exchange Ltd
• Madras Stock Exchange Ltd.,
• MCX Stock Exchange
• National Stock Exchange of India Ltd.
• Over The Counter Exchange Of India Ltd.
• The Stock Exchange, Mumbai
• Uttar Pradesh Exchange Assoc Ltd.

Should you Invest in Sun Pharma Share?

Sun Pharma has a ‘buy’ recommendation from the firm, with a targeting price of ₹1,100. The company’s continued progress in the speciality segment, according to CLSA, will drive its operational leverage and determine its valuation. Sun Pharma’s profit forecasts for FY22-FY23 were lifted between 1-5 percent to mirror the Q3 beat.

The report outlined a Consolidated Overall Income of ₹9848.82 Crore for the quarter that ended on September 30, 2021. It was down by -.23 percent from the previous quarter’s total income of ₹9871.26 Crore but up by 11.81 percent from last year’s Total Income of ₹8808.91 Crore in the same quarter. In the most recent quarter, the company generated a net profit after tax of ₹2088.73 crores.

Revenues are expected to rise by 9.3 percent year-on-year to ₹9656.9 crores, owing to a 12 percent year-on-year increase in domestic formulations to ₹3083.1 Crore. Taro’s sales are predicted to increase by 6.8% year-on-year to ₹1103.6 crores, while US (ex-Taro) sales are expected to increase by 4.2 percent year-on-year to ₹1799.9 crores. EBITDA margins are predicted to fall by 73 basis points to 26.5 percent, while EBITDA is expected to increase by 6.4 percent year-on-year to ₹2559.1 crores. Adjusted PAT is expected to fall by 5.6 percent year-on-year to ₹1749 crore. Hence, Sun Pharma stock price is expected to see a rise and is best for the long-term investment plan of the investors.

FAQ’s about Sun Pharma Share Price